DC FieldValueLanguage
dc.contributorSchool of Optometryen_US
dc.contributorChinese Mainland Affairs Officeen_US
dc.creatorShan, SWen_US
dc.creatorDo, CWen_US
dc.creatorLam, TCen_US
dc.creatorLi, HLen_US
dc.creatorStamer, WDen_US
dc.creatorTo, CHen_US
dc.date.accessioned2021-07-09T02:26:43Z-
dc.date.available2021-07-09T02:26:43Z-
dc.identifier.issn0021-9541en_US
dc.identifier.urihttp://hdl.handle.net/10397/90443-
dc.language.isoenen_US
dc.publisherJohn Wiley & Sonsen_US
dc.subjectGlaucomaen_US
dc.subjectOutflow facilityen_US
dc.subjectROCK inhibitoren_US
dc.subjectThrombospondin-1en_US
dc.subjectTrabecular meshworken_US
dc.titleThrombospondin-1 mediates Rho-kinase inhibitor-induced increase in outflow-facilityen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.doi10.1002/jcp.30492en_US
dcterms.abstractRho-kinase (ROCK) inhibitors, a novel class of anti-glaucoma agents, act by increasing the aqueous humor outflow through the conventional trabecular meshwork pathway. However, the downstream signaling consequences of the ROCK inhibitor are not completely understood. Our data show that Y39983, a selective ROCK inhibitor, could induce filamentous actin remodeling, reduced cell motility (as measured by cell migration), and transepithelial resistance in primary human TM (hTM) cells. After 2 days Y39983 treatment of hTM cells, a proteomic study identified 20 proteins whose expression was significantly altered. Pathway analysis of those proteins revealed the involvement of the p53 pathway, integrin signaling pathway, and cytoskeletal pathway regulation by Rho GTPase. Thrombospondin-1 (TSP1), a matricellular protein that is increased in glaucoma patients, was downregulated fivefold following Y39983 treatment. More importantly, both TSP1 antagonist leucine–serine–lysine–leucine (LSKL) and small interfering RNA (siRNA) reduced TSP1 gene and protein expressions as well as hTM cell migration. In the presence of Y39983, no further inhibition of cell migration resulted after LSKL and TSP1 siRNA knockdown. Likewise, LSKL triggered a dose-dependent increase in outflow facility in ex vivo mouse eyes, to a similar extent as Y39983 (83.8% increase by Y39983 vs. 71.2% increase by LSKL at 50 µM). There were no additive effects with simultaneous treatment with LSKL and Y39983, supporting the notion that the effects of ROCK inhibition were mediated by TSP1.en_US
dcterms.accessRightsembargoed accessen_US
dcterms.bibliographicCitationJournal of cellular physiology, 2021, Early view, https://doi.org/10.1002/jcp.30492en_US
dcterms.isPartOfJournal of cellular physiologyen_US
dcterms.issued2021-
dc.identifier.scopus2-s2.0-85078859913-
dc.identifier.eissn1097-4652en_US
dc.description.validate202107 bcvcen_US
dc.description.oaNot applicableen_US
dc.identifier.FolderNumbera0960-n02-
dc.description.fundingSourceRGCen_US
dc.description.fundingSourceOthersen_US
dc.description.fundingTextThis work is supported by Research Grants Council Funding Body Ref. No.: 15104819en_US
dc.description.pubStatusEarly releaseen_US
dc.date.embargo0000-00-00 (to be updated)en_US
Appears in Collections:Journal/Magazine Article
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.